Evaluation of disease activity, disability and quality of life in patients with persistently active refractory juvenile idiopathic (chronic) arthritis (JIA) treated with monoclonal anti-tumor necrosis factor-α antibody (Infliximab)

被引：0
|
作者：
Gerloni, V
Pontikaki, I
Desiati, F
Lupi, E
Gattinara, M
Fantini, F
机构：
[1] Univ Milan, Chair Rheumatol, I-20122 Milan, Italy
[2] Gaetano Pini Inst, Ctr Rheumat Children, Milan, Italy
来源：
JOURNAL OF RHEUMATOLOGY | 2001年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
T110
引用
收藏
页码：67 / 67
页数：1
相关论文
共 42 条
  • [11] Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
    Kavanaugh, A
    St Clair, EW
    McCune, WJ
    Braakman, T
    Lipsky, P
    [J]. JOURNAL OF RHEUMATOLOGY, 2000, 27 (04) : 841 - 850
  • [12] Longterm anti-tumor necrosis factor-α treatment in patients with refractory rheumatoid arthritis:: Relationship between insulin resistance and disease activity
    Seriolo, Bruno
    Ferrone, Carmela
    Cutolo, Maurizio
    [J]. JOURNAL OF RHEUMATOLOGY, 2008, 35 (02) : 355 - 357
  • [13] Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-α antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease
    Hommes, DW
    van Dullemen, HM
    Levi, M
    Van der Ende, A
    Woody, J
    Tytgat, GNJ
    van Deventer, SJH
    [J]. HAEMOSTASIS, 1997, 27 (06) : 269 - 277
  • [14] Tumor Necrosis Factor-α-308 a/G Gene Polymorphism in Children with Juvenile Idiopathic Arthritis: Relation to Disease Activity, Damage and Disability
    Gheita, Tamer
    El Gazzar, Iman
    Fathy, Hanan
    El-Din, Abeer Nour
    Rasheed, Enas Abdel
    Bassyouni, Rasha
    Kenawy, Sanaa
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [15] TUMOR NECROSIS FACTOR-α-308 A/G GENE POLYMORPHISM IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: RELATION TO DISEASE ACTIVITY, DAMAGE AND DISABILITY
    El Gazzar, I. I.
    Fathi, H. M.
    Gheita, T. A.
    El-Din, A. M. Nour
    Rasheed, E. Abdel
    Bassyouni, R. H.
    Kenawy, S. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 670 - 670
  • [16] Short-term treatment with monoclonal anti-tumor necrosis factor-α antibody in refractory long-standing rheumatoid arthritis.
    Fantini, F
    Sinigaglia, L
    Zeni, S
    Cagnoli, M
    Favalli, EG
    Colombelli, P
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S227 - S227
  • [17] Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-α Agents
    Kestens, Christine
    van Oijen, Martijn G. H.
    Mulder, Charlotte L. J.
    van Bodegraven, Ad A.
    Dijkstra, Gerard
    de Jong, Dirk
    Ponsioen, Cyriel
    van Tuyl, Bas A. C.
    Siersema, Peter D.
    Fidder, Herma H.
    Oldenburg, Bas
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (07) : 826 - 831
  • [18] A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor α agents
    Lurati, A.
    Pontikaki, I.
    Teruzzi, B.
    Desiati, F.
    Gerloni, V.
    Gattinara, M.
    Cimaz, R.
    Fantini, F.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1602 - 1607
  • [19] Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-α treatment
    Higashida, J
    Wun, T
    Schmidt, S
    Naguwa, SM
    Tuscano, JM
    [J]. JOURNAL OF RHEUMATOLOGY, 2005, 32 (11) : 2109 - 2115
  • [20] Pharmacokinetics and pharmacodynamics of infliximab, an anti-tumor necrosis factor-alpha monoclonal antibody, following single subcutaneous administrations in rheumatoid arthritis patients.
    Zhu, YW
    Pendley, C
    Sisco, D
    Westhovens, R
    Durez, P
    Bouman-Thio, E
    van Hartingsveldt, B
    Everitt, DE
    Graham, MA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P43 - P43
12345